Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LAPATINIB Cause Gamma-glutamyltransferase increased? 18 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 18 reports of Gamma-glutamyltransferase increased have been filed in association with LAPATINIB. This represents 0.9% of all adverse event reports for LAPATINIB.

18
Reports of Gamma-glutamyltransferase increased with LAPATINIB
0.9%
of all LAPATINIB reports
1
Deaths
14
Hospitalizations

How Dangerous Is Gamma-glutamyltransferase increased From LAPATINIB?

Of the 18 reports, 1 (5.6%) resulted in death, 14 (77.8%) required hospitalization.

Is Gamma-glutamyltransferase increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LAPATINIB. However, 18 reports have been filed with the FAERS database.

What Other Side Effects Does LAPATINIB Cause?

Diarrhoea (382) Disease progression (227) Palmar-plantar erythrodysaesthesia syndrome (182) Malignant neoplasm progression (173) Nausea (161) Metastases to central nervous system (160) Neutropenia (160) Vomiting (155) Asthenia (148) Fatigue (139)

What Other Drugs Cause Gamma-glutamyltransferase increased?

FINGOLIMOD (635) ACETAMINOPHEN (442) METHOTREXATE (421) ATORVASTATIN (376) RIBOCICLIB (375) LETROZOLE (323) DEXAMETHASONE (292) CYCLOPHOSPHAMIDE (277) CARBOPLATIN (262) NIVOLUMAB (261)

Which LAPATINIB Alternatives Have Lower Gamma-glutamyltransferase increased Risk?

LAPATINIB vs LAPATINIB DITOSYLATE LAPATINIB vs LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN LAPATINIB vs LARONIDASE LAPATINIB vs LAROTRECTINIB LAPATINIB vs LASILIX

Related Pages

LAPATINIB Full Profile All Gamma-glutamyltransferase increased Reports All Drugs Causing Gamma-glutamyltransferase increased LAPATINIB Demographics